Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth

[1]  Lin Chang,et al.  FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.

[2]  H. Hallen-Adams,et al.  Fungi in the healthy human gastrointestinal tract , 2017, Virulence.

[3]  K. Nishida,et al.  The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome , 2017, Journal of applied microbiology.

[4]  M. Pimentel,et al.  Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage , 2016, BMC Gastroenterology.

[5]  Lixiang Li,et al.  Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis , 2016, BMC Gastroenterology.

[6]  Clarence C Lee,et al.  Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome , 2015, Scandinavian journal of gastroenterology.

[7]  S. Kim,et al.  Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[8]  S. Ayis,et al.  Randomised clinical trial: a liquid multi‐strain probiotic vs. placebo in the irritable bowel syndrome – a 12 week double‐blind study , 2014, Alimentary pharmacology & therapeutics.

[9]  W. Chung,et al.  Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double‐blind, placebo‐controlled trial , 2014, Journal of gastroenterology and hepatology.

[10]  R. Gearry,et al.  The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study , 2013, International journal of clinical practice.

[11]  W. Chung,et al.  The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial , 2012, Journal of clinical gastroenterology.

[12]  M. Pimentel,et al.  The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome , 2012, Digestive Diseases and Sciences.

[13]  P. Whorwell,et al.  Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report , 2011, The American Journal of Gastroenterology.

[14]  C. Choi,et al.  A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces boulardii in Irritable Bowel Syndrome: Effect on Quality of Life , 2011, Journal of clinical gastroenterology.

[15]  O. Palsson,et al.  Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders: A Double-blind Study , 2011, Journal of clinical gastroenterology.

[16]  P. Shekelle,et al.  Safety of Probiotics to Reduce Risk and Prevent or Treat Disease , 2011 .

[17]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[18]  W. Chey,et al.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.

[19]  S. Vanner,et al.  Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS , 2010, Gut.

[20]  M. Pimentel,et al.  Abnormal Breath Testing in IBS: A Meta-Analysis , 2010, Digestive Diseases and Sciences.

[21]  A. Gasbarrini,et al.  Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case–control study in irritable bowel syndrome , 2005, Alimentary pharmacology & therapeutics.

[22]  A. Gasbarrini,et al.  Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth , 2005, Alimentary pharmacology & therapeutics.

[23]  P. Whorwell,et al.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress , 1997, Alimentary pharmacology & therapeutics.

[24]  P. Shekelle,et al.  Safety of probiotics used to reduce risk and prevent or treat disease. , 2011, Evidence report/technology assessment.

[25]  C. Nord,et al.  The normal human anaerobic microflora. , 1982, Scandinavian journal of infectious diseases. Supplementum.